DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: GILENYA (fingolimod, FTY720)
       *****************************************************
       #Post#: 882--------------------------------------------------
       (Abst.) Lymphomatoid papulosis in patient on Gilenya for MS
   DIR By: agate
       Date: July 31, 2015, 1:17 pm
       ---------------------------------------------------------
       From Multiple Sclerosis Journal, July 30, 2015:
       --- Quote ---
       > Lymphomatoid papulosis: A cutaneous lymphoproliferative
       disorder in a patient on fingolimod for multiple sclerosis
       >
       > Amal PR Samaraweera
       > Division of Clinical Neuroscience, Queen’s Medical Centre,
       University of Nottingham, UK
       >
       > Stuart N Cohen
       > Nottingham University Hospitals NHS Trust, UK
       >
       > Ela M Akay
       > Nottingham University Hospitals NHS Trust, UK
       >
       > Nikos Evangelou
       > Division of Clinical Neuroscience, Queen’s Medical Centre,
       University of Nottingham, UK/Nottingham University Hospitals NHS
       Trust, UK
       > Nottingham University Hospitals NHS Trust, Derby Road,
       Nottingham, NG7 2UH, UK. nikos.evangelou@nottingham.ac.uk
       >
       >
       > Background:
       >
       > Fingolimod was the first oral disease-modifying treatment for
       relapsing–remitting multiple sclerosis. It has previously been
       associated with the development of lymphoma.
       >
       > Objective:
       >
       > To describe a case of lymphomatoid papulosis, a CD30+
       cutaneous lymphoproliferative disorder, in a patient taking
       fingolimod.
       >
       > Methods:
       >
       > Case study.
       >
       > Results:
       >
       > Our patient developed lymphomatoid papulosis 2 months after
       starting fingolimod. Histology confirmed the diagnosis. The drug
       was withdrawn. Resolution began only 2 days later.
       >
       > Conclusions:
       >
       > Lymphomatoid papulosis is a benign subtype of cutaneous T-cell
       lymphoma, but up to 20% of cases can transform to a malignant
       course. Patients on fingolimod and physicians caring for them
       should be mindful of the need to monitor the skin.
       --- End Quote ---
       [Emphasis added.]
       The abstract can be seen here
  HTML http://msj.sagepub.com/content/early/2015/07/30/1352458515597568?papetoc.
       *****************************************************
       Page 1 of 1